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Abstract
Effective Botulinum Toxin injection point for
treatment of headache
Won-Jae Lee, D.D.S., M.S.
Department of Dentistry
The Graduate School, Yonsei University
(Directed by Professor Kyung-Seok Hu, D.D.S., Ph.D.)
The underlying causes of migraine are often nerve and muscle disorders,
which has led to botulinum toxin type A (BoNT-A) injection gaining traction
as a viable treatment option. However, previous injection sites on the
temporalis muscle for treating migraine were determined by observing the
trigger point of migraines, and it is unsure whether these are the most
anatomically effective sites for injection (Whitcup et al., 2014).
This study performed an extensive analysis of published research on the
morphology of the temporalis muscle in order to provide an anatomical
guideline on how to distinguish the temporalis muscle and temporalis tendon
by observing the surface of the patient’s face. Furthermore, it was found that
Sihler’s staining could be applied to the temporalis muscle in order to identify
accurate and effective BoNT-A injection sites for treating migraines.
Twenty-one hemifaces of cadavers (16 males, 5 females; mean age, 81.0
years; age range, 63–93 years) were used in this study. The experiment was
divided into two steps: (1) morphologically analyzing the temporalis region of
the cadavers and (2) applying Sihler’s staining to the temporalis muscle and
tendon.
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The posterior border of the temporalis tendon was classified into three
types according to its location relative to five reference lines: in Type I the
posterior border of the temporalis tendon is located in front of reference line
L2 (4.8%, 1/21), in Type Ⅱ it is located between reference lines L2 and L3
(85.7%, 18/21), and in Type Ⅲ it is located between reference lines L3 and L4
(9.5%, 2/21).
The vertical distances between the horizontal line passing through the
jugale (LH) and the temporalis tendon along each of reference lines L0, L1, L2,
L3, and L4 were 29.74±6.87 mm (mean±SD), 45.06±8.84 mm, 37.76±11.18 mm,
42.50±7.59 mm, and 32.14±0.47 mm, respectively; the corresponding vertical
distances between LH and the temporalis muscle were 55.02±8.25 mm,
74.99±9.90 mm, 73.97±10.12 mm, 55.24±13.25 mm, and 47.56±11.41 mm.
Sihler’s staining shows that the anterior and posterior branches of the deep
temporal nerve run through the anterior and posterior fibers of the temporalis
muscle, respectively.
BoNT-A should be injected into the temporalis muscle at least 45 mm
vertically above the zygomatic arch. This will ensure that the muscle region is
targeted and so produce the greatest clinical effect with the minimum
concentration of BoNT-A. In order to easily identify the temporalis muscle in
a clinical setting, the second finger should be placed on the bottom corner of
the zygomatic arch; the tip of the thumb will then be located 45 mm from the
zygomatic arch.
                                                                          
Key words : Migraine, Botulinum toxin type A, Temporalis, Injection site,
Sihler stain
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Effective Botulinum Toxin injection point for
treatment of headache
Won-Jae Lee, D.D.S., M.S.
Department of Dentistry, The Graduate School,
Yonsei University
(Directed by Professor Kyung-Seok Hu, D.D.S., Ph.D.)
Ⅰ. INTRODUCTION
Headaches can be clinically classified into primary and secondary types.
Primary headaches occur without underlying organic diseases and can be
further classified into migraine, tension-type headache, and cluster headaches.
Among the three classifications, migraines have the strongest hereditary
associations. Patients suffering from migraines often show hypersensitive
reactions to light, sounds, and touch, and during severe episodes this can lead
to photophobia, acousticophobia, and olfactophobia. Although migraines are not
life-threatening, they can severely impair the everyday lives of affected
patients.
The underlying causes of migraines are often nerve and muscle disorders,
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which has led to botulinum toxin type A (BoNT-A) gaining traction as a
viable treatment option (Carruthers and Carruthers, 2001; Göbel et al., 2001;
Heckmann et al., 2001). BoNT-A reportedly has fewer side effects than the
drugs that are commonly used to migraines. Furthermore, a single BoNT-A
treatment can last up to 4 months, in contrast to the fairly short-term effects
of orally administered drugs and lidocaine injections (Dodick et al., 2004; Chan
et al., 2009).
The US Food and Drug Administration (FDA) recognized the safety and
effectiveness of BoNT-A by approving 31 injection sites for BoNT-A on
October 2010. Among them, four injection sites on each side of the temporalis
muscle were suggested. These injection sites were approved after observing
the clinical ramifications of BoNT-A injections originally aimed at treating
tension-type headaches. However, anatomical research focused on the neural
distribution of the head and neck area is needed to form the basis for accurate
and specific BoNT-A injections.
The specific mechanism by which BoNT-A relieves pain has not yet been
identified (Robertson et al., 2012; Cernuda et al., 2014), but it can be
hypothesized that the relief of muscular tension, and transcytosis and the
retrograde transport of BoNT-A suppresses the diffusion of neurotransmitters
across the peripheral nerve (Ramachandran and Yaksh, 2014). These
mechanisms suppress both peripheral and central sensitization, providing relief
for patients suffering from peripheral and central neuritis. Since BoNT-A acts
on nerve endings, an extensive and accurate anatomical understanding of the
nerve endings of the targeted muscle is critical for obtaining maximum relief
with the minimum concentration of BoNT-A.
Invasive anatomical procedures are of limited use when attempting to find
effective BoNT-A injection sites due to the risk of damaging the muscle and
the target nerve endings. In contrast, Sihler’s staining, which dyes myelin
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sheaths, provides a minimally invasive and effective method of tracking nerve
endings within a targeted muscle (Won et al., 2011; Yang et al., 2013).
Since migraines often occur in the temporal region, the temporalis muscle is
the main target for BoNT-A injections aimed at treating migraines. The
application of Sihler’s staining to the temporalis muscle will facilitate accurate
and extensive observations of the neural distribution and nerve endings of the
deep temporal nerve.
The morphology of the temporalis muscle restricts the ability to identify
effective injection sites by simply observing the associated neural distribution,
and the pharmaceutical application of BoNT-A in the tendon region is highly
ineffective. Sihler’s staining must therefore be accompanied by morphological
investigations of the temporalis muscle and temporalis tendon.
This study performed an extensive analysis of published research on the
morphology of the temporalis muscle in order to provide an anatomical
guideline on how to distinguish the temporalis muscle and temporalis tendon
by observing the surface of the patient’s face. Furthermore, it was found that
Sihler’s staining could be applied to the temporalis muscle in order to identify
accurate and effective BoNT-A injection sites for treating migraines.
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Ⅱ. MATERIALS & METHODS
1. Materials
Twenty-one hemifaces of cadavers (16 males, 5 females; mean age, 81.0
years; age range, 63–93 years) were used in this study. All of the cadavers
were donated by Yonsei Medical Center. None of the cadavers had any
damage or previous surgery in the temporal region. The experiment was
divided into two steps: (1) morphologically analyzing the temporalis region of
the cadavers and (2) applying Sihler’s staining to the temporalis muscle and
tendon.
2. Methods
2.1. Morphological analysis of the temporalis muscle and tendon
The skin, subcutaneous tissue, and superficial and deep temporal fasciae of
the temporalis muscle were first removed, which allowed the temporalis tendon
and temporalis muscle to be clearly identified. This study used several
anatomical points as standard markers to measure the width, height, and
length of the temporalis muscle.
In order to provide a clear clinical guideline for BoNT-A injection in the
temporalis region, the jugale and zygomatic arch were used as structural
anatomical markers to morphologically delineate the temporalis muscle. The
reference points and lines shown in Fig. 1 were established prior to making
the measurements described below.
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Fig. 1. Reference points and lines based on surface anatomical structures.
Jugale: A landmark on the skull at which the temporal and frontal processes
of the zygomatic bone meet. LH: The horizontal line passing through the
jugale. L0: The vertical line passing through the jugale. L1: The line evenly
dividing L0 and L2. L2: The vertical line passing through the anterior outer
margin of the ear. L3: The line evenly dividing L2 and L4. L4: The vertical
line passing through the posterior outer margin of the ear.
Horizontal line LH was used as a standard for measuring the vertical
distances separately to the temporalis muscle and temporalis tendon using
vertical lines L0–L4 as defined in Fig. 1. All measurements were made using
a protractor and digital calipers (CD-15CP, Mitutoyo, Kawasaki, Japan) capable
of measuring to the nearest 0.01 mm.
2.2. Sihler’s staining for identifying the neural distribution of the temporalis
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muscle
Sihler’s staining was applied to reveal the neural distribution of the
temporalis muscle. Sihler’s staining involves the seven steps described below.
Although the duration of staining varies according to thickness, it usually
takes up to 5 months.
Fixation
The temporalis muscle that had been dissected from the cadaver was
placed in 10% unneutralized formalin for 1 month. The duration of formalin
fixation varied according to the specimen size and thickness. The formalin did
need not to be replaced unless it became polluted.
Maceration
The fixed specimens were washed for 1 hour in running water, and then
stored in 3% potassium hydroxide solution (3% aqueous potassium hydroxide
solution containing 0.2 ml of 3% hydrogen peroxide per 100 ml). The fixed
specimens became partially transparent after 3 to 4 weeks of storage, during
which time the potassium hydroxide solution was replaced daily.
Decalcification
The macerated specimens were stored for 4 weeks in Sihler’s solution I,
which comprises glacial acetic acid, glycerin, and 1% aqueous chloral hydrate
mixed in a 1:1:6 ratio. This solution was replaced weekly.
Staining
Adequately decalcified specimens were stained for 3 to 4 weeks in Sihler’s
solution II, which comprises Ehrlich’s hematoxylin, glycerin, and 1% aqueous
chloral hydrate mixed in a 1:1:6 ratio. The staining period was varied
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according to the specimen size and thickness. A viewing box was used to
decide when the Ehrlich’s hematoxylin had permeated the specimen sufficiently.
Destaining
Stained specimens are again placed in Sihler’s solution I so that they
became transparent. This step was necessary since Sihler’s solution II dyes
both the nerves and muscle tissue purple. The specimens were checked
frequently until adequate transparency was achieved. Depending on the
specimen, the process took up to 2 hours.
Neutralization
The acidified specimen was neutralized in a 0.05% lithium carbonate
solution for about 1 hour before being washed in running water for 30
minutes.
Clearing
The specimen was placed in a thymol crystal containing glycerin solution.
The concentration of glycerin was increased in four stages (40%, 60%, 80%,
and 100% glycerin), before being finally stored in a 100% glycerin solution.
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Ⅲ. RESULTS
1. Posterior border of the temporalis tendon
The ear and reference lines L2, L3, and L4 was used to clearly delineate
the temporalis tendon. The posterior border where the temporalis tendon
disperses can be classified into the following three types:
1. In Type I, the posterior border of the temporalis tendon is located in
front of L2 (Fig. 2). In this type the distance between the jugale and L2 was
49.6±6.0 mm (mean±SD), and it occurred in 1 of the 21 cases (4.8%).
2. In Type Ⅱ, the posterior border of the tendon is located between L2 and
L3 (Fig. 3). In this type the distance between the jugale and L3 was
70.2±5.1mm, and it occurred in 18 of the 21 cases (85.7%).
3. In Type III, the posterior border of the tendon is located between L3 and
L4 (Fig. 4). In this type the distance between the jugale and L4 was
90.0±5.3mm, and it occurred in 2 of the 21 cases (9.5%).
There were no cases where the tendon dispersed beyond L4.
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Fig. 2. Type I, in which the posterior border of the temporalis tendon is
located in front of L2 (4.8%, 1/21). The distance between the jugale and L2
was 49.6±6.0 mm.
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Fig. 3. Type Ⅱ, in which the posterior border of the temporalis tendon is
located between L2 and L3 (85.7%, 18/21). The distance between the jugale
and L3 was 70.2±5.1 mm.
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Fig. 4. Type Ⅲ, in which the posterior border of the temporalis tendon is
located between L3 and L4 (9.5%, 2/21). The distance between the jugale and
L4 was 90.0±5.3 mm.
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2. Vertical border of the temporalis tendon and temporalis muscle
The vertical distances between LH and the temporalis tendon along the L0,
L1, L2, L3, and L4 reference lines were 29.74±6.87 mm, 45.06±8.84 mm,
37.76±11.18 mm, 42.50±7.59 mm, and 32.14±0.47 mm, respectively; the
corresponding vertical distances between LH and the temporalis muscle were
55.02±8.25 mm, 74.99±9.90 mm, 73.97±10.12 mm, 55.24±13.25 mm, and
47.56±11.41 mm (Table 1).
Table 1. The vertical distance of the temporalis tendon and mucle from LH
Points　
The vertical length
of the tendon
The vertical length
of the muscle
L0 29.7±6.8 55.0±8.3
L1 45.1±8.8 75.0±10.0
L2 37.8±11.2 74.0±10.1
L3 42.5±7.6 55.2±13.3
L4 32.1±0.5 47.6±11.4
Values are expressed in millimeters (mm).
3. Intramuscular nerve distribution of the temporalis muscle
The temporalis is a masticatory muscle that can be divided into anterior,
middle, and posterior regions. Sihler’s staining showed that the anterior branch
of the deep temporal nerve runs through the anterior fibers of the temporalis
muscle, which provides upward elevation of the mandible. The posterior branch
of the deep temporal nerve runs through the posterior fibers of the temporalis
muscle, which provides backward elevation of the mandible. The middle branch
of the deep temporal nerve runs through the middle fibers of the temporalis
muscle (Fig. 5).
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Fig. 5. The temporalis muscle and temporalis tendon could be clearly
distinguished after Sihler’s staining. The temporalis tendon appeared as a fan
beginning at the point where it inserted into the temporalis muscle. The
temporalis muscle occupied the remaining area. The nerve trunk of the deep
temporal nerve traversed the temporalis tendon. The nerve endings of the deep
temporal nerve mainly dispersed in the temporalis muscle.
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Ⅳ. DISCUSSION
Migraine treatments can be divided largely into pharmacotherapy and
physiotherapy. Pharmacotherapy can be further classified into the oral
administration of amitriptyline and topiramate or the injection of BoNT-A and
lidocaine. Physiotherapy involves exercise, positional release therapy, and
massage therapy (Fernández-de-Las-Peñas et al., 2006; Bendtsen, 2009;
Weatherall, 2015). However, the oral administration of drugs for extended
periods poses the risk of significant side effects for those with cardiovascular
disease, cerebrovascular disease, peripheral vascular disease, liver disease, and
pregnancy. Furthermore, there is currently insufficient scientific evidence for
the physiological benefits of physiotherapy (Levin, 2010; Chen, 2012).
The mechanism by which BoNT-A relieves migraines is not yet clear.
There is empirical evidence suggesting that BoNT-A has minimal side effects,
and a single treatment lasts up to 4 months. The FDA has approved 31 sites
at which BoNT-A can be injected for treating migraines. However, since these
sites were chosen based on observations of the trigger point of migraines, it is
unclear whether these are the most anatomically effective sites for
injection-based treatments. In order to find the most anatomically effective
injection sites, an extensive study of the nerve endings in the temporalis
muscle is necessary.
Sihler’s staining was used in this study to observe the neural distribution
in the temporalis region. The tendon and muscle regions could be clearly
distinguished after applying Sihler’s staining, which was bolder in the tendon
region. The anterior, middle, and posterior branches of the deep temporal nerve
traverse the temporalis tendon into the intramuscular layer. A notable
characteristic of the deep temporal nerve was that all of its branches traverse
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without dispersion in the temporalis tendon—only when the nerve branches
reached the muscle region did the nerve endings disperse.
There is anatomical evidence supporting the clinical practice of injecting
BoNT-A into the temporalis muscle while avoiding the temporalis tendon,
including because (1) there is pharmaceutical evidence that BoNT-A acts in
the muscle region (Durham and Cady, 2011) and (2) the neural distribution of
the temporalis muscle indicates that its nerve endings are densely located in
the muscle region. This anatomical evidence can be used to produce a
guideline for injection sites on the temporalis muscle. Since the temporalis
region can be morphologically divided into the tendon and muscle regions, a
guideline on the anatomical surfaces in which BoNT-A should be injected can
be suggested. Based on the results of this study, we suggest that the
temporalis tendon is horizontally located approximately 45 mm from LH, and
any location more than 45 mm vertically above LH can be considered the
muscle region.
The jugale is a part of the zygomatic bone that horizontally follows the
superior margin of the zygomatic arch. Horizontal line LH, which passes the
jugale, coincides with the superior margin of the zygomatic arch. It can
therefore be clinically applied as the superior margin of the zygomatic arch.
We conclude that the temporalis tendon stretches 45 mm from the superior
margin of the zygomatic arch.
The temporalis tendon can be easily found by first aligning the thumb and
the first finger in a flat stretched-out state and then placing the second finger
on the inferior margin of the zygomatic arch. This will result in the tip of the
thumb being located approximately 45 mm from the superior margin of the
zygomatic arch (Fig. 6). This method makes it easy to identify the temporalis
muscle and therefore also the effective injection site for BoNT-A.
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Fig. 6. The position of the temporalis tendon can be easily determined first
aligning the thumb and first finger in a flat stretched-out state and then
placing the second finger on the inferior margin of the zygomatic arch. The tip
of the thumb is then located approximately 45 mm from the superior margin of
the zygomatic arch.
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Ⅴ . CONCLUSION
An easily identifiable and effective injection site for BoNT-A on the
temporalis muscle has been suggested based on the results of this research.
BoNT-A should be injected into the temporalis muscle at least 45 mm
vertically above the zygomatic arch. This will ensure that the target is the
muscle region, which will produce the greatest clinical effect using the
minimum concentration of BoNT-A. The main findings of this study can be
summarized as follows:
1. The temporalis tendon is shaped like a fan. The most distant point of
the tendon region is located 45 mm from the zygomatic arch. Therefore, the
site of BoNT-A injection into the temporalis muscle should be at least 45 mm
from the zygomatic arch.
2. Sihler’s staining shows that the nerve endings that BoNT-A acts on are
densely dispersed in the temporalis muscle, which indicates that the muscle
region is an effective site for BoNT-A injection.
3. In order to easily identify the temporalis muscle in a clinical setting, the
second finger should be placed on the bottom corner of the zygomatic arch.
The tip of the thumb will then be located 45 mm from the zygomatic arch.
Clinicians with a comprehensive understanding of the results reported in
this paper will be easily able to determine an effective BoNT-A injection site
for migraine treatment.
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Abstract (in korean)
편두통 치료를 위한 관자근의 보툴리눔독소 주사점에 대한 
연구
<지도교수 허 경 석>
연세대학교 대학원 치의학과
이 원 재
두통은 일상생활에서 우리가 흔하게 겪는 증상으로, 일반적으로 편두통과 긴장
성두통이 가장 빈번하게 발생한다. 두통의 치료방법 중 보툴리눔독소 주사법은 주
로 관자부위에 주사를 하게 되는데, 비침습적이고, 부작용이 적으며, 치료 효과가 
탁월하여 일반적으로 널리 이용되지만, 관자근의 해부학적 정보를 기반으로한 정
확하고 효과적인 보툴리눔독소 주사점에 대한 연구는 부족한 실정이다. 이에 본 연
구에서는 관자근에 대한 표면해부학적 분석을 시행하여 보툴리눔독소 주사 시 임
상에서 쉽게 적용가능한 주사점을 제시하는데 그 목적이 있다.
재료로는 한국인 성인 시신 머리 21쪽을 사용하였다. 관자근의 힘줄부분이 노출
되도록 조심스럽게 해부한 후 얼굴의 표지점을 중심으로 기준점과 기준선을 정하
여 관자근에대한 형태학적 분석을 시행하였으며, 그 후 관자근을 적출하여 Sihler
염색을 시행하였다.
관자근의 힘줄부분 형태는 크게 세 가지 형태로 구분되었다. TypeⅠ은 관자근의 
힘줄부분이 L2의 앞모서리까지 작게 형성된 형태로 약 5%(1/21)에서 관찰되었으
며, TypeⅡ는 관자근의 힘줄부분이 L2와 L3 사이에 위치하는 경우로 약 
85%(18/21)에서 관찰되었고, TypeⅢ는 관자근의 힘줄부분이 L3와 L4 사이에 위치
하는 경우로 약 10%%(2/21)에서 관찰되었다. 관자근의 힘줄부분은 광대활의 L0,
L1, L2 지점에서 각각 29.7mm, 45.0mm, 37.7mm 떨어진 곳까지 존재하였으며, 관
자근의 힘살부분은 광대활의 L0, L1, L2, L3, L4 지점에서 각각 55.0mm, 74.9mm,
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73.9mm, 55.2mm, 47.5mm 떨어진 곳까지 위치하였다.
Sihler 염색 결과, 관자근에는 깊은관자신경의 앞가지와 뒤가지가 관자근 전체에 
분포하는 것을 관찰할 수 있었으며, 특히 관자근의 힘줄부분 깊숙한 곳에서 근육으
로 들어온 신경의 줄기가 힘살부분으로 넘어가면서 무수히 많은 신경말단가지를 
분지하는 것을 확인하였다.
관자근은 하나의 근육에 힘줄부분과 힘살부분이 동시에 존재하는 근육으로, 이 
근육의 힘줄부분에 의해 강력한 힘이 작용한다. 하지만 두통 치료를 위한 주사 시,
보툴리눔독소는 이 근육의 힘살부분에 주입되어야 하며, 힘줄부분에 주입될 경우 
그 약리학적 효과를 기대하기 어렵다. 본 연구의 결과 관자근에서 힘줄부분이 위쪽
으로 차지하는 영역은, 표면해부학적 지표인 광대활을 기준으로 약 45mm 떨어진 
곳까지 존재하였으며, 그 위쪽으로는 모두 힘살의 영역인 것을 확인하였다. 또한 관
자근의 힘줄부분이 뒤쪽으로 차지하는 영역은 대부분의 경우에서 귀의 가운데를 
지나는 수직선(L3)까지 존재하였다.
또한 Sihler 염색 결과 관자근에 분포하는 깊은관자신경 줄기는 관자근의 힘줄부
분 깊은 곳에서부터 이 근육으로 들어와 힘줄부분을 지나 힘살부분에서부터 신경
말단가지를 분지하는 것을 관찰하였다. 결론적으로 관자근의 보툴리눔독소 주사
는, 실질적으로 보툴리눔독소가 작용하는 신경말단 부위에 주사되어야 하며, 따라
서 관자근에서 힘줄부분이 아닌 힘살부분에 주사되어야 한다. 또한 본 연구의 결과 
관자근의 힘줄부분은 광대활을 기준으로 약 45mm 떨어진 곳까지 존재하였으며,
이 계측값은 광대활에서부터 엄지손가락 길이만큼 떨어진 곳으로 쉽게 확인이 가
능하다.
따라서 본 연구의 결과는 실제 환자의 얼굴 표면에서 광대활을 기준으로 관자근
의 힘줄부분이 어느 부분까지 존재하는지 예측할 수 있으며, 이는 보툴리눔독소를 
이용한 편두통 치료에서 보다 더 안전하고 효과적인 주사점을 제시할 수 있을 것이
라 생각한다.
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